Hidden RNA Brake Inside Mitochondria Slows Fat Cell Formation in Obese Mice

Deep inside the energy factories of our fat cells, a newly discovered molecule appears to act as a biological brake on weight gain. In a study published in Nature Communications, researchers in China report that a circular RNA molecule that lodges itself inside mitochondria—the tiny organelles that generate most of a cell’s chemical energy—rises in abundance when nutrient overload stresses white adipose tissue, and that this molecule actively restrains the formation of new fat cells. The finding adds a surprising new layer to the biology of obesity and points toward a potential therapeutic target for obesity-related metabolic diseases.

The molecule, which the team named circRNA BRAKE—an acronym for Birc6-circRNA Repressing Adipogenesis and Krebs-cycle Energy—belongs to a class of genetic material called circular RNAs. Unlike the familiar linear messenger RNAs that carry protein-building instructions from DNA, circular RNAs are formed when a stretch of RNA loops back on itself and is joined end to end, creating a closed ring that is unusually stable and resistant to degradation. Most circular RNAs studied so far float in the cell’s cytoplasm or nucleus, where they act as sponges for other molecules or regulators of gene expression. What makes BRAKE remarkable is where it was found: inside mitochondria themselves, a location where RNA molecules of any kind are comparatively rare and poorly understood.

The researchers began by systematically profiling the circular RNAs present in mitochondria isolated from the white adipose tissue of obese male mice. White adipose tissue is the body’s main fat-storage depot, and its proper function depends on a delicate balance between the formation of new adipocytes—the process known as adipogenesis—and the metabolic activity of existing ones. When the team compared obese animals with lean controls, one circular RNA stood out: BRAKE was markedly upregulated in the mitochondria of obese mice’s fat tissue. That pattern suggested the molecule might be part of the cellular response to nutrient excess rather than an incidental byproduct.

To test whether BRAKE was merely a marker of obesity or an active participant in it, the researchers turned to loss-of-function experiments. When they specifically knocked down circRNA BRAKE in the adipocytes of male mice, the animals lost body weight, accumulated less fat, and showed improved insulin sensitivity. In other words, removing the brake allowed the metabolic machinery to shift in a direction that counteracted the consequences of obesity. Complementary in vitro studies reinforced the picture: in cell culture, circRNA BRAKE inhibited adipogenesis, the differentiation of precursor cells into mature fat cells.

The mechanistic heart of the study lies in how BRAKE exerts its influence. The team found that the circular RNA physically binds to ATP5A, a core component of ATP synthase—the molecular turbine embedded in the inner mitochondrial membrane that manufactures adenosine triphosphate, the universal energy currency of cells. By binding ATP5A, BRAKE disrupts the assembly of the ATP synthase complex. A partially assembled or destabilized ATP synthase works less efficiently, and the result is a measurable drop in ATP production within the cell.

That drop in ATP has consequences that ripple outward. Reduced cellular energy status dampens mTORC1 signaling, a master regulatory pathway that senses nutrient and energy availability and, when conditions are favorable, drives cell growth and differentiation. mTORC1 is well known to promote adipogenesis: when nutrients are abundant and ATP is plentiful, the pathway encourages precursor cells to commit to the fat-cell lineage. By throttling ATP synthesis and thereby weakening mTORC1 signaling, BRAKE effectively tells the tissue to hold back on manufacturing new fat cells even while the animal is in a state of nutrient overload. The molecule’s name—BRAKE—captures this function precisely.

This mechanism reframes how scientists think about mitochondrial dysfunction in obesity. Impaired adipogenesis is increasingly recognized as a contributor to obesity-associated metabolic disorders, and mitochondrial dysfunction has long been implicated in that impairment. But the idea that a mitochondria-localized circular RNA could tune the assembly of the electron transport chain’s flagship enzyme—and, through it, the entire adipogenic program—had not been demonstrated before. The study suggests that the mitochondrial genome’s neighborhood, and the RNA molecules that traffic within it, may be far more influential in systemic metabolism than previously appreciated.

Importantly, the findings are not confined to mice. The researchers examined omental white adipose tissue—the fat that wraps around the abdominal organs and is strongly linked to metabolic risk—obtained from patients with obesity. There, too, mitochondrial levels of circRNA BRAKE were elevated, and those levels were inversely correlated with the bioenergetic function of the patients’ mitochondria. In other words, the more BRAKE present in the mitochondria, the weaker the organelles’ energy-generating capacity. This human correlation lends clinical weight to the mouse experiments and suggests that the same molecular brake may operate in human fat tissue.

The therapeutic implications are tantalizing but must be handled with care. Because adipocyte-specific knockdown of BRAKE in mice reduced body weight and improved insulin sensitivity, one might imagine drugs that silence the circular RNA as a future treatment for obesity-related metabolic disease. Yet the biology cuts both ways: BRAKE appears to be a restraint mechanism, and its elevation in obesity may represent the body’s attempt to limit further fat expansion under nutrient stress. Interfering with such a brake could have complex, context-dependent effects, and the study’s authors frame circRNA BRAKE as a potential target rather than a validated drug destination. Delivering RNA-targeting therapeutics specifically to adipocyte mitochondria would also pose substantial technical challenges that remain unsolved.

What the study firmly establishes is a new principle: circular RNAs can reside inside mitochondria, bind core components of the oxidative phosphorylation machinery, and thereby regulate both cellular differentiation and whole-body metabolism. As sequencing technologies probe deeper into the mitochondrial RNA landscape, molecules like BRAKE may prove to be the first members of an entire regulatory class. For now, the image that lingers is a striking one—a ring-shaped RNA molecule, born from a gene called Birc6, threading its way into the cell’s power plants and gently jamming the gears of the ATP turbine, all in the service of keeping fat formation in check when the body is drowning in nutrients.

Subject of Research: A mitochondria-localized circular RNA that regulates adipogenesis and energy metabolism by disrupting ATP synthase assembly

Article Title: Mitochondria-localized circRNA BRAKE restrains adipogenesis under nutrient overload by disrupting ATP synthase assembly in mice

Article References: Mitochondria-localized circRNA BRAKE restrains adipogenesis under nutrient overload by disrupting ATP synthase assembly in mice. (n.d.). https://doi.org/10.1038/s41467-026-78378-z

Image Credits: AI Generated

DOI: 10.1038/s41467-026-78378-z

Keywords: circular RNA, mitochondria, adipogenesis, obesity, ATP synthase, mTORC1 signaling, white adipose tissue, insulin sensitivity, non-coding RNA, metabolic disease, ATP5A, energy metabolism